Educational Course on the Management of GvHD Oct 2026

The Goal

The goal of the GvHD interactive course is to share experience and recommendations on ECP usage in Lung cGvHD, to provide latest trends on the use of combination therapies in the treatment of aGvHD, and to share data on overall survival in acute and chronic GvHD.

Agenda

Download Agenda PDF

Day 1 - 21 October 2026

Arrival of participants

19.00 – 19.15
Meeting in the lobby

19.15
Dinner

Day 2 - 22 October 2026

08:45 – 09:00
Welcome & introduction - Prof Hildegard Greinix &Therakos Healthcare Stakeholder Engagement Department

09:00 – 09:15
How do I improve response and survival in Lung GvHD? - Prof Hildegard Greinix

09:15 – 10:15
Lung GvHD and chronic allograft dysfunction: two sides of the same coin? - Prof Saskia Bos

10:15 – 10:45
ECP immunomodulation proposed mechanism of action - Prof James Hutchinson

10:45 – 11:00
Coffee Break

11:00 – 11:30
Early diagnosis process for Lung GvHD patients; Recommendations for early diagnosis of Lung GvHD - Prof Hildegard Greinix

11:30 – 12:00
ECP in cGvHD – a focus on skin and lung manifestations - Prof Hildegard Greinix

12:00 – 12:15
EBMT ERS (European Respiratory Society) guidelines - Prof Saskia Bos

12:15 – 12:45
Patient cases discussion – Lung GvHD - All

12:45 – 13:45
Patient cases discussion – Lung GvHD - All

13:45 – 14:15
Managing GvHD with combination therapy: a focus on aGVHD and potential implications for cGvHD - Prof Nicolaus Kröger

14:15 – 14:45
ECP impact on survival in acute GvHD - Prof Daniele Avenoso

14:45 – 15:00
Interactive discussion – What’s the pivotal role of ECP in the current treatment landscape? - All

15:00 – 15:15
Final remarks and close - Faculty

ECP: Extracorporeal Photopheresis, GvHD: Graft versus Host Disease, EBMT: European Society for Blood and Marrow Transplantation

For this course, participants are required to submit one patient case for discussion 15 days in advance of the session

All speakers are subject to contract.
This is a commercial programme run by Therakos (UK) Ltd
This information is intended for healthcare professionals based in Europe and the Middle East.

Hosted by

Prof Dr Hildegard Greinix

Past President, Worldwide Network for Blood & Marrow Transplantation (WBMT), Medical University of Vienna

Brought to you by the Therakos Institute

This is a commercial programme run by Therakos (UK) Ltd.

Our Centres of Excellence (CoE) Programme is for customers only. If you are interested in attending our CoE courses please contact your Sales Representative.

Explore related courses

Mar 4 - 5, 2026

Educational Course on GvHD

Steigenberger Hotel Vienna, Austria

Find out more

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Educational Course on the Management of GvHD